Analysis of AR-modulated ERG expression in archival tumor biopsies from patients enrolled in the COU-AA-302 trial showed that ERG gene fusion expression (2+ Edel cancers), previously considered as unfavorable prognostic factor for survival, was associated with the greatest clinical benefit from abiraterone treatment [17]. Here, AR is linked to neoplasm.